News Headlines

31. Cellular Origins Advances Automation For Scalable Cell Therapy Manufacturing In Collaboration With Immatics 5/5/2026

    Cellular Origins, enabling the manufacturing of cell therapies at scale, today announced a collaboration with Immatics a late-stage clinical biopharmaceutical company and the global leader in precision targeting of PRAME for the production of Immatics’ immuno-oncology cell therapies.

32. Viralgen Partners With Elaaj Bio To Advance Gene Therapy Program For CDKL5 Deficiency Disorder 5/5/2026

    Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD).

33. Epicrispr Biotechnologies And Forge Biologics Announce AAV Development And cGMP Manufacturing Partnership 5/5/2026

    Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to support the development and manufacturing of EPI-321, Epicrispr’s investigational AAV gene therapy for facioscapulohumeral muscular dystrophy (FSHD).

34. RoosterBio And Made Scientific Announce Strategic Technology And Supply Partnership To Expand Scalable MSC And Extracellular Vesicle Manufacturing 5/5/2026

    Made Scientific, Inc., a U.S.-based clinical and commercial cell therapy contract development and manufacturing organization (CDMO), and RoosterBio, Inc., a leading supplier of human mesenchymal stem cells (MSCs), engineered bioprocess media, and bioprocess development services, today announced a strategic partnership integrating RoosterBio's mesenchymal stem cell (MSC) and extracellular vesicle (EV) manufacturing platforms into Made Scientific's end-to-end CDMO offering which spans from initial process development through commercial-scale GMP manufacturing.

35. BioCryst Announces European Licensing Agreement With Irish Affiliate Of Neopharmed Gentili For Navenibart In Hereditary Angioedema 5/4/2026

    BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe.

36. HAS Group Announces Strategic Investments In Biodelphis Therapeutics 5/4/2026

    HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics today announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases.

37. Novelty Nobility Taps AGC Biologics To Further Develop Bispecific Drug Candidate 5/3/2026

    Novelty Nobility, a clinical-stage biotech company based in South Korea, expanded its manufacturing agreement with AGC Biologics, your friendly CDMO expert, to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics’ facility in Chiba, Japan.

38. Halo Pharma Emerges As Standalone CDMO Following Siegfried Acquisition Of Noramco 5/1/2026

    Halo Pharma (the “Company”), a leading CDMO partner to the pharmaceutical industry and previous division of Noramco Group, is now operating as a standalone business following Siegfried’s acquisition of Noramco Group’s small molecule API assets.

39. KM Biologics Co. Ltd. Enters Into A Technology Collaboration With Serum Institute Of India 4/30/2026

    Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) hereby announces that KM Biologics Co., Ltd., a group company of Meiji Seika Pharma, has entered into a technology collaboration with Serum Institute of India Private Limited (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer, for the development and manufacturing of a Japanese encephalitis vaccine, and has achieved the first milestone under this collaboration.

40. Huahui Health And BeOne Medicines Enter Into A Global Exclusive Option, License And Collaboration Agreement For Innovative Oncology Drug HH160 4/30/2026

    Huahui Health today announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.